Laser Phase Plate Breakthrough Allows Electron Microscopes to See the Smallest Human Proteins

For decades, structural biologists have faced a frustrating paradox: the tools powerful enough to see the building blocks of life are mostly blind to the vast majority of them. Cryo-electron microscopy (cryo-EM) revolutionized biology and earned a Nobel Prize by revealing the atomic structures of large molecular machines. Yet, it struggles to generate clear images of proteins smaller than 70 kilodaltons.[1][2]

Because approximately 90 percent of the human proteome falls below this size threshold, researchers have been effectively locked out of observing the bulk of the cellular machinery. Now, two research teams from UC Berkeley and the Chan Zuckerberg Biohub have demonstrated a functional "laser phase plate" (LPP), a device that solves this 80-year-old contrast problem.[3][4][5][6]

The core limitation of conventional cryo-EM is a lack of contrast. Biological molecules are composed of light elements like carbon, nitrogen, and oxygen, which barely scatter the electron beam used to image them. To generate a visible image, researchers traditionally have to push the microscope out of focus, a compromise that creates contrast but destroys high-resolution detail.[2][4][7][8]

The theoretical solution—a phase plate that shifts the electron beam to create contrast while perfectly in focus—was proposed by Dutch scientist Frits Zernike for light microscopy nearly a century ago, but adapting it for electrons proved notoriously difficult. Previous physical phase plates suffered from rapid electrostatic charging, rendering them unstable for routine use.[2][4][6][7]

The new LPP technology bypasses physical materials entirely, using light to manipulate electrons. As detailed in a newly published paper in Science, the system traps a continuous-wave laser inside a mirrored Fabry-Pérot cavity.[2][8]

The laser beam bounces back and forth nearly 10,000 times, building up a steady-state intensity of 350 to 400 gigawatts per square centimeter—an energy density roughly 100 million times brighter than the surface of the sun. When the microscope's electron beam passes through this intense optical field, the electrons experience a 90-degree phase shift.[2][3][7][8]

This shift generates stark image contrast without requiring the microscope to be defocused, preserving the fragile high-resolution data. The primary claim of the LPP developers is that this contrast boost allows cryo-EM to resolve molecules previously considered too small to image.[2][5]

The evidence for this is strong, anchored by benchmark tests on hemoglobin, a 64-kilodalton blood protein that sits at the absolute lower limit of conventional cryo-EM capabilities. In paired experiments comparing images taken with the laser off versus the laser on, the Berkeley team demonstrated that the LPP improved the resolution of the hemoglobin structure by up to 44 percent.[2][5][8]

The system also successfully imaged aldolase, a standard benchmark enzyme, with significantly enhanced clarity. A secondary claim is that the LPP does not degrade the ultimate resolution limit of the microscope, a problem that plagued earlier physical phase plates.[2][3]

Evidence for this comes from a parallel preprint released by the Biohub team, which details a "crossed" or dual-laser phase plate design. Using this dual-cavity system, the researchers imaged apoferritin—a highly stable protein used to calibrate microscopes—at a resolution of 1.8 angstroms.[5][7]

Achieving this near-atomic resolution proves that the intense laser field is not trading high-end resolution for low-end contrast, a critical validation for structural biologists. Beyond isolated proteins, the most significant anticipated impact of the LPP is in cryo-electron tomography (cryo-ET).[5][7]

While single-particle cryo-EM requires purifying millions of identical proteins and freezing them in isolation, cryo-ET captures 3D images of proteins in their native, messy environment inside intact cells. Because cells are thick and crowded, the signal-to-noise ratio in conventional cryo-ET is exceptionally poor.[2][4][6]

Researchers claim the LPP will provide the dramatic step forward in contrast needed to identify individual proteins within the cellular "forest". While the theoretical basis for this is sound, the empirical evidence is currently limited to early imaging of thick E. coli samples, which showed a clear contrast boost but have not yet yielded full cellular atlases.[5][6][7][8]

Despite the breakthrough, there is transparent uncertainty regarding the timeline for widespread adoption. The LPP is not yet a commercial, plug-and-play device. The engineering tolerances required to maintain the optical cavity are extreme.[5][8]

The mirrors must be polished to a surface roughness below one angstrom—roughly the diameter of a single atom—and aligned to within a thousandth of a degree. Furthermore, the system is exquisitely sensitive to contamination; a single speck of dust entering the cavity will absorb the intense laser energy, instantly burning up and destroying the mirror.[5][8]

Because of these extreme sensitivities, independent experts caution that the current iteration is akin to "first light through a telescope" rather than a finished laboratory instrument. While the entire laser apparatus has been miniaturized to fit inside a four-inch module that drops into a standard Thermo Fisher Krios microscope column, maintaining the laser's stability requires constant, active tuning.[5][7]

Researchers describe the process as "like a surfer trying to hold perfectly to the peak of a wave, not for seconds, but for half an hour at a stretch". The path forward involves transitioning the LPP from a bespoke physics experiment into a robust, automated tool.[8]

Biohub engineers are currently working to stabilize the microscope integration, with the goal of beginning routine tomographic data collection by the end of the year. If these engineering hurdles are cleared, the technology is expected to be commercialized and deployed to structural biology cores worldwide.[6][8]

By illuminating the 90 percent of the proteome that has remained in the dark, the LPP promises to accelerate drug discovery and fundamentally rewrite our understanding of the molecular machinery driving human health and disease.[3][6]